Marc Dechamps will talk about the journey of Bioxodes from natural product to clinical development of drug candidate, for patients suffering from acute haemorrhagic stroke. He will also discuss the current financial difficulties for clinical stage Biotech companies to find enough funding to progress in the development of a drug candidate. There will be plenty of room for Q&A.

What information is generated concerning a patient, where is it stored, how can it be shared among various healthcare providers, and how can I, as a patient, access my own data? Does a system of patient-centric care already exist in Belgium? And what significance does "patient-centric care" hold for an individual patient? This keynote adopts a storytelling approach, offering insights from the perspective of a patient on the quest to unravel these inquiries.

In this presentation, we explore the dynamic world of sharing and reusing health data within the pharmaceutical industry and healthcare sector. We begin by addressing the major obstacles to data sharing, such as technical, legal, and ethical challenges, and how these can impede progress. We then highlight how the pharmaceutical sector utilizes health data for the development of new medications and treatments, and the benefits this brings to both patients and society.

A critical part of our discussion focuses on the protection of patient privacy. We examine how to leverage the benefits of data sharing while safeguarding the privacy and rights of individuals. Finally, we look ahead to the future possibilities of data sharing, focusing on technological innovations, policy changes, and collaborations that have the potential to improve healthcare worldwide.

This presentation aims to build an understanding of the current landscape and stimulate a dialogue on how we can work together towards a future where health data is shared safely, ethically, and effectively for the well-being of everyone.

The presentation will share the experience of Kantify, a Belgian company using AI to improve human health in cancer and rare diseases through target and small molecule discovery. The presentation will explain why and how an AI-first company pivoted to a "TechBio" company, i.e a company at the interface of technology and biology, and became a new player in the biotechnology landscape. It will provide very practical examples of how AI accelerates drug discovery, directly drawn from Kantify's experience and portfolio. It will also cover some of the opportunities, challenges and questions introduced by this new technology, so that participants can understand and translate the impact of AI for their own practice, organization, and professional journey. 

The presentation will start to provide some context and definitions related to the fields mentioned in the title. Specific attention will go to different types of PKPD modelling, explaining the differences between bottom-up and top-down modelling approaches. The latter 2/3 of the presentation will provide inspiring examples for instance how PBPK modelling and simulation is already supporting drug development decisions, clinical trial design and model-informed dosing in special populations (e.g. in neonates and during pregnancy). Conclusions of the presentation will zoom out again and seek links with AI/ML, providing future perspectives and challenges.